Dr. Braunschweig on Selecting Between Transplant and CAR T-Cell Therapy in DLBCL


Ira Braunschweig, MD, discusses factors to consider when selecting between autologous stem cell transplant, allogeneic stem cell transplant, and CAR T-cell therapy in diffuse large B-cell lymphoma.

Ira Braunschweig, MD, director, Stem Cell Transplant Program, clinical program director, Hematologic Malignancies, Montefiore Medical Center, associate professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses factors to consider when selecting between autologous stem cell transplant (ASCT), allogeneic stem cell transplant (allo-SCT), and CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

In patients with chemotherapy-sensitive DLBCL, ASCT remains the standard of care, says Braunschweig. This is likely due to the fact that the field has decades worth of experience in treating this patient population with ASCT.

However, CAR T-cell therapy appears to be the clear treatment choice for patients with primary refractory DLBCL, Braunschweig explains.

Historically, patients who progressed after ASCT received an allo-SCT, which can have curative potential, says Braunschweig. However, many patients experience graft-versus-host disease and ongoing health issues following allo-SCT.

Alternatively, if patients can tolerate the toxicities that tend to arise within the first few weeks after CAR T-cell therapy, they have a decreased risk for long-term health issues compared with allo-SCT, Braunschweig says.

Moreover, unlike with transplant, CAR T-cell therapy eliminates the need to aggregate antitumor response, which may make it a more appealing option for patients, concludes Braunschweig.

Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
© 2024 MJH Life Sciences

All rights reserved.